Company Overview and News

 
Chinese co-living firm Harbour launches US$1.58 billion fund to build more rental housing

2018-05-25 scmp
Harbour, a Shanghai-based co-living space operator backed by Gaw Capital Partners and Trustbridge Partners, has launched a 10 billion yuan (US$1.58 billion) buyout fund with a financial leasing company to acquire land plots for rental flat development, on top of another US$1 billion fund with Gaw to acquire existing properties for flat conversions.

 
UPDATE 1-Brazil's Marfrig names five potential bidders for Keystone, shares rise

2018-05-23 reuters
SAO PAULO, May 23 (Reuters) - Brazilian meatpacking company Marfrig Global Foods SA said five companies have qualified to participate in a second phase of bidding for Keystone Foods LLC, lifting its shares 10 percent.

 
Podcast | Takeover battle for Fortis over as Munjal-Burmans bid gets a nod?

2018-05-11 moneycontrol
There seems to be an end in sight for the month-and-a-half long bidding war between multiple parties from different countries wishing to acquire Fortis. The winning bid which now belongs to Sunil Munjal and the Burman family will now be considered by Fortis’s shareholders for approval. And that is our Story of the Day. My name is Rakesh, and this Moneycontrol.

 
Fortis board chose Munjals-Burmans due to certainty, liquidity issues

2018-05-11 livemint
Gurgaon: Majority of Fortis Healthcare’s board opted for the Munjals-Burmans offer keeping in mind the certainty and liquidity issues, the company’s director Brian W. Tempest said on Friday.

 
Fortis Healthcare posts biggest intraday fall in 4 weeks

2018-05-11 thehindubusinessline
Shares of Fortis Healthcare Ltd fell as much as 3.2 per cent to Rs 148, their biggest intraday percentage fall in nearly four weeks.

 
WeDoctor raises US$500 million in private share sale

2018-05-09 scmp
WeDoctor Holdings, an online health care services provider backed by Tencent Holdings, has completed a US$500 million private share sale, in the second major equity financing deal in China’s nascent “health-tech” sector in three weeks.

 
Manipal Health further sweetens bid for Fortis

2018-05-07 freepressjournal.in
New Delhi : Manipal Health Enterprises on Sunday further sweetened its offer for Fortis Healthcare (FHL), raising the value to Rs 8,358 crore.

 
India's Manipal raises bid for Fortis, outlines cash injection plan

2018-05-06 reuters
May 6 (Reuters) - India’s privately-held Manipal Hospitals sweetened its bid for rival Fortis Healthcare Ltd on Sunday, offering to inject 21 billion rupees ($314 million) to help the ailing hospital operator meet its immediate cash needs.

 
Manipal Health further sweetens offer for Fortis Healthcare, raises value to Rs8,358 crore

2018-05-06 livemint
New Delhi: Manipal Health Enterprises on Sunday revised yet again its offer for Fortis Healthcare Ltd (FHL), raising the value to Rs8,358 crore.

 
Arpwood to advise Fortis on bids

2018-05-05 freepressjournal.in
New Delhi : Fortis Healthcare on Friday said it has appointed Arpwood Capital to advise its board on various sale bids. The firm will act as financial advisor to the board to provide its independent opinion on the offers received or to be received from bidders for a potential significant equity investment and/or acquisition or restructuring of its assets, and on the appropriateness of the process put into place for dealing with the said offers, the healthcare major said.

 
Fortis appoints Arpwood Capital to advise on sale bids

2018-05-04 livemint
New Delhi: Fortis Healthcare on Friday said it has appointed Arpwood Capital Private Ltd to advise the board on various sale bids.

 
IHH revises upward takeover offer for India's Fortis

2018-05-03 thestar.com.my
IHH said in a filing with Bursa Malaysia that it has issued an enhanced revised proposal letter to the board of Fortis on May 1, to reiterate IHH’s seriousness and commitment to an investment in Fortis.

 
The Power of Diversity

2018-05-02 scmp
In a global economy, companies that seek to grow beyond the local market need to employ a pool of talent representing diverse points of view and the knowledge to succeed. Diversity can be a competitive differentiator.

 
From the Dean

2018-05-02 scmp
The principle that people should be hired for positions, and promoted or rewarded, solely on the basis of their talents and performance, and not because of their gender, ethnic origins or other functionally irrelevant demographic attributes, is widely accepted today. But beyond a sense of being on the right side of social progress, does employing a more diverse workforce boost performance?

 
A Global Perspective

2018-05-02 scmp
The results speak for themselves. Fosun International, a multinational company, with its roots in China, has a strong track record of making overseas acquisitions, accelerating the growth of subsidiaries and generating significant returns. What the world does not usually see is its philosophy to manage its rapid-growing business portfolio across five continents. We sat down with Mr Xu Xiaoliang, Executive Director and Co-president of Fosun International, to find out about its globalization strategy and talent management system behind the scenes.

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

2018-05-25 - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

2018-05-25 - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...